免疫抑制相关的EBV阳性间变性大细胞淋巴瘤伴有 BRAF V600E 突变

免疫组化抗体神器

好评必备! 免费下载

  --本文经《美国外科病理学杂志》授权发布,其他媒体转载或引用须经《美国外科病理学杂志》同意,否则追究法律责任。

  在移植后接受免疫抑制剂 / 免疫调节剂的患者中,发生医源性淋巴组织增生性疾病已被报道。 新型生物制剂,如 TNF-α阻滞剂 和 JAK 抑制剂也被证明在许多疾病中有效,包括类风湿关节炎、炎症性肠病(溃疡性结肠炎和克罗恩病)、 银屑病以及其他疾病等。
  与免疫抑制剂或风湿病相关的淋巴组织增生性疾病的一个显著困境是在于这些疾病过程是否与药物或自身免疫性疾病相关。 本文 中, 我们描述了 1 例与类风湿关节炎和使用 JAK 抑制剂相关的 EB 病毒阳性的间变性大细胞淋巴瘤。 通过对患者皮肤和肺活检组 织的分子学检测(荧光原位杂交、OncoScan 微阵列以及焦磷酸测序)的比较,发现了 BRAF V600E 基因的驱动突变,这个发现至关重要,因为此突变通路可以作为潜在的治疗靶点。

  Am J Surg Pathol 2019;43:140–146
  美国外科病理学杂志中文版2019年第三期摘要NO.5
  (徐恩伟 翻译/审校)
  The American Journal of Surgical Pathology中文版声明:
  ©2018 Wolters Kluwer Health
  The material is published by Wolters Kluwer Health with the permission of American Journal of Surgical Pathology.No part of this publication may be reproduced in any form,stored in a retrieval system or transmitted in any form,by any means,without prior written permission from Wolters Kluwer Health.Opinions expressed by the authors and advertisers are not necessarily those of the American Journal of Surgical Pathology, its affiliates,or of the Publisher.The American Journal of Surgical Pathology,its affiliates,and the Publisher disclaim any liability to any party for the accuracy,completeness,efficacy,or availability of the material contained in this publication (including drug dosages) or for any damages arising out of the use or non-use of any of the material contained in this publication.
  Although advertising material is expected to conform to ethical (medical) standards,inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

  【本文经《美国外科病理学杂志》授权发布,其他媒体转载或引用须经《美国外科病理学杂志》同意 ,否则追究法律责任;所有文章仅供公益交流,不代表本站立场。欢迎提供素材、资料等,投稿邮箱: tougao@91360.com,一经采纳将给予稿费】
责任编辑: zh025
0 0 0

扫一扫下载91360客户端